In a sensational lawsuit, a former Mallinckrodt (MNK) employee claims that she was fired for repeatedly warning the drug maker about a host of allegedly illegal activities designed to boost sales of a key drug.
Those practices included running a “sham” patient assistance program and refusing to provide payers with clinical data that would be used for making coverage decisions. Moreover, executives were allegedly unaware of the ingredients in the best-selling Achtar drug, which is used to treat infantile spasms and often prescribed for more than a dozen other maladies.
About the Author Reprints
